Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $57

Benzinga Newsdesk www.benzinga.com Negative 60.4%

Neg 60.4% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $65 to $57.